To Evaluate IOL Position, Clinical Outcome of PanOptix in High Myopic Cataract Patients
NCT ID: NCT05042856
Last Updated: 2021-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2021-10-01
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improved Operation of Low Intraocular Pressure in Phacoemulsification for Patients With High Myopia Complicated With Cataract
NCT05201677
High Intraocular Pressure After Cataract Surgery
NCT05834465
Study of the Correlation Between Preoperative Precise Biometrics, Spatial Assessment and Postoperative Visual Quality in Cataract Patients
NCT04833491
Posterior Capsulotomy in Cataract Complicated With Primary Posterior Capsule Opacification.
NCT03701139
Comparison of Manual Super Small Incision Cataract Surgery and Phacoemulsification
NCT01146964
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective of this study to investigate the refractive and visual performance of PanOptix and explore their correlation with ELP change, capsular bending formation, IOL tilt/decentration in high myopic cataract patients.
PanOptix IOL provides good refractive outcomes and visual quality because of few ELP change, fast capsular bending formation and few tilt and decentration in high myopic cataract patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PanOptix
All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
PanOptix IOL implantation
All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PanOptix IOL implantation
All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 26 ≤Axial length\<30mm, IOL power ≥6D (PanOptix IOL power is available +6D-+30D )
* Eyes with corneal astigmatism less than 1.0D (IOLMaster 700, Carl Zeiss Meditec AG)
* Eyes with pupil diameter between 3 and 5.5 mm (iTrace, Tracey Technology, Houston, Texas, USA)
* Eyes with angle kappa and angle Alpha ≤0.50 mm (iTrace);
* Eyes with corneal spherical aberration ≤ 0.50 (Pentacam).
Exclusion Criteria
* Serious intraoperative complications, glaucoma, pseudoexfoliation syndrome, uveitis, macular degeneration or other retinal impairment
* Moderate-severe dry eye, corneal scarring, amblyopia
* Patients who can't cooperate with post-op 3 months follow-up.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wenzhou Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yune Zhao
Vice president of Eye Hospital of Wenzhou Medical University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
yune zhao, MD
Role: STUDY_CHAIR
Wenzhou Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ophthalmology and Optometry Hospital
Wenzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
zhao yun-e
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZYY-PanOptix IOL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.